Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Satri-cel is filed for gastric cancer approval in China.
The company reckons its immunotherapy could improve on Keytruda.
“We need all the capital we can get our hands on," the company states.
Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
